Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application ... In the prespecified subgroup of ...

When is the Path of Exile 2 release date? Path of Exile 2 has now evolved from its initial role as effectively a large expansion to become its own full game, with completely new mechanics ...

Despite these claims, Gunn took to Threads to deny the rumor that Pyg and Scarecrow will join Hush, Clayface, and Robin in Part 2. However, this statement implies the latter three characters will ...

With that in mind, here are all the rumors we've heard about the Nintendo Switch 2 and what we’d like to see. This original rumor suggested that Nintendo had moved the release date of its next ...

If you want to know what to expect from the Nintendo Switch 2 then we're here to help. We've rounded-up all the latest rumours on Nintendo's next console, including leaks on the Switch 2 release ...

AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely watched lung cancer medicine, a decision ...

2013 -Board has recommended a dividend of Rs.2.50/- per equity shares of Rs.10/-each. 2014 --Board has recommended a dividend of Rs.2.50/- per equity shares of Rs.10/-each for the year 2014.

8316.T Sumitomo Mitsui Financial Group, Inc.